Literature DB >> 21324100

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.

Jürgen Bauer1, Petra Büttner, Rajmohan Murali, Ichiro Okamoto, Nicholas A Kolaitis, Maria T Landi, Richard A Scolyer, Boris C Bastian.   

Abstract

Oncogenic BRAF mutations are more frequent in cutaneous melanoma occurring at sites with little or moderate sun-induced damage than at sites with severe cumulative solar ultraviolet (UV) damage. We studied cutaneous melanomas from geographic regions with different levels of ambient UV radiation to delineate the relative effects of cumulative UV damage, age, and anatomic site on the frequency of BRAF mutations. We show that BRAF-mutated melanomas occur in a younger age group on skin without marked solar elastosis and less frequently affect the head and neck area, compared to melanomas without BRAF mutations. The findings indicate that BRAF-mutated melanomas arise early in life at low cumulative UV doses, whereas melanomas without BRAF mutations require accumulation of high UV doses over time. The effect of anatomic site on the mutation spectrum further suggests regional differences among cutaneous melanocytes.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324100      PMCID: PMC3107974          DOI: 10.1111/j.1755-148X.2011.00837.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  27 in total

1.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.

Authors:  Jürgen Bauer; John A Curtin; Dan Pinkel; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2006-08-03       Impact factor: 8.551

2.  Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program.

Authors:  Anne M Lachiewicz; Marianne Berwick; Charles L Wiggins; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2008-05       Impact factor: 8.551

Review 3.  Unveiling hair follicle stem cells.

Authors:  Leilei Yang; Ruiyun Peng
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

4.  MC1R germline variants confer risk for BRAF-mutant melanoma.

Authors:  Maria Teresa Landi; Jürgen Bauer; Ruth M Pfeiffer; David E Elder; Benjamin Hulley; Paola Minghetti; Donato Calista; Peter A Kanetsky; Daniel Pinkel; Boris C Bastian
Journal:  Science       Date:  2006-06-29       Impact factor: 47.728

5.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

6.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.

Authors:  Wendy Liu; John W Kelly; Melanie Trivett; William K Murray; John P Dowling; Rory Wolfe; Graham Mason; Jill Magee; Christopher Angel; Alexander Dobrovic; Grant A McArthur
Journal:  J Invest Dermatol       Date:  2006-12-07       Impact factor: 8.551

7.  Associations between silicone skin cast score, cumulative sun exposure, and other factors in the ausimmune study: a multicenter Australian study.

Authors:  Robyn M Lucas; Anne-Louise Ponsonby; Keith Dear; Bruce V Taylor; Terence Dwyer; Anthony J McMichael; Patricia Valery; Ingrid van der Mei; David Williams; Michael P Pender; Caron Chapman; Alan Coulthard; Trevor Kilpatrick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

8.  Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Robert C Millikan; Pamela A Groben; Honglin Hao; Dawn Tolbert; Marianne Berwick; Klaus Busam; Colin B Begg; Dianne Mattingly; David W Ollila; Chiu Kit Tse; Amanda Hummer; Julia Lee-Taylor; Kathleen Conway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

9.  Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls.

Authors:  Yu-mei Chang; Jennifer H Barrett; D Timothy Bishop; Bruce K Armstrong; Veronique Bataille; Wilma Bergman; Marianne Berwick; Paige M Bracci; J Mark Elwood; Marc S Ernstoff; Richard P Gallagher; Adèle C Green; Nelleke A Gruis; Elizabeth A Holly; Christian Ingvar; Peter A Kanetsky; Margaret R Karagas; Tim K Lee; Loïc Le Marchand; Rona M Mackie; Håkan Olsson; Anne Østerlind; Timothy R Rebbeck; Peter Sasieni; Victor Siskind; Anthony J Swerdlow; Linda Titus-Ernstoff; Michael S Zens; Julia A Newton-Bishop
Journal:  Int J Epidemiol       Date:  2009-04-08       Impact factor: 7.196

10.  Improving melanoma classification by integrating genetic and morphologic features.

Authors:  Amaya Viros; Jane Fridlyand; Juergen Bauer; Konstantin Lasithiotakis; Claus Garbe; Daniel Pinkel; Boris C Bastian
Journal:  PLoS Med       Date:  2008-06-03       Impact factor: 11.069

View more
  65 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 3.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 4.  New treatments for metastatic melanoma.

Authors:  Craig Gedye; David Hogg; Marcus Butler; Anthony M Joshua
Journal:  CMAJ       Date:  2014-02-18       Impact factor: 8.262

5.  Melanoma--the pieces of the puzzle finally start coming together! Preface.

Authors:  Alan Spatz; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2011-04-03       Impact factor: 6.603

6.  Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update.

Authors:  Giovanni Paolino; Elisa Moliterni; Dario Didona; Valentina Garelli; Paola Corsetti; Teresa Lopez; Antonio Giovanni Richetta; Carmen Cantisani; Ugo Bottoni; Stefano Calvieri
Journal:  Med Oncol       Date:  2014-12-17       Impact factor: 3.064

Review 7.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

8.  Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Authors:  Robert V Rawson; Peter A Johansson; Nicholas K Hayward; Nicola Waddell; Ann-Marie Patch; Serigne Lo; John V Pearson; John F Thompson; Graham J Mann; Richard A Scolyer; James S Wilmott
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

9.  [Targeted therapies for melanoma].

Authors:  U Leiter; F Meier; C Garbe
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

10.  Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis.

Authors:  Ruifeng Guo; Xianfu Wang; Jie Chen; Ellizabeth Gillies; Kar-Ming Fung; Shibo Li; Lewis A Hassell
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.